Education
About Us
Working with TipRanks
Follow Us
Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
DRTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.75 - $4.39
Previous CloseN/A
Volume116.73K
Average Volume (3M)57.15K
Market Cap
$183.69M
Enterprise Value$166.97M
Total Cash (Recent Filing)$457.75K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.92
Next Earnings
May 21, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding70,380,570
10 Day Avg. Volume33,550
30 Day Avg. Volume57,147
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-155.46
Enterprise Value/Ebitda-4.84
Forecast
1Y Price Target
$7.33Price Target Upside175.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Alpha Tau Medical Ltd News
PremiumCompany Announcements
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges
PremiumCompany Announcements
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress
PremiumCompany Announcements
Alpha Tau Medical to Showcase Alpha DaRT at March Investor ConferencesPremiumCompany Announcements
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts
---
Bulls Say, Bears Say
Bulls Say
Clinical ResultsAlpha Tau Medical reported positive interim results for the first eight patients receiving a combination of Alpha DaRT and Keytruda for the treatment of recurrent unresectable or metastatic head and neck squamous cell carcinoma, with a systemic objective response rate of 75%.
ManufacturingThe Hudson, NH facility is slated to complete its first phase of construction and come online for production of Alpha DaRT, indicating progress in manufacturing capabilities.
Regulatory ProgressAlpha DaRT has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot of the U.S. FDA to accelerate market access for patients with recurrent glioblastoma multiforme.
Bears Say
Clinical TrialsThe expansion of clinical trials in various types of visceral organs could potentially allow Alpha DaRT to target a broader set of indications.
Market CompetitionOptions to invest in publicly traded radiopharma names have grown increasingly scarce, making DRTS an overlooked exception.
Regulatory UncertaintyThe company expects to receive a response from PMDA in Japan on pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer by the end of 2024.
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.65% Other Institutional Investors
99.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $1.75 and its highest was $4.39 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $183.69M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is May 21, 2025 which is in 56 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on Mar 12, 2025. The company reported -$0.135 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.005.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.13.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 70,380,570 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.135 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -1.504%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
---
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (175.56% Upside)
$7.33 (175.56% Upside)
Hedge Fund Trend
Decreased
By 60.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ―
Last 30 Days ―
Last 30 Days ―
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.90%
12-Months-Change
Fundamentals
Return on Equity
-43.16%
Trailing 12-Months
Asset Growth
-19.73%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
---
DRTS Stock 12 Month Forecast
Average Price Target
$7.33
▲(175.56% Upside)
Technical Analysis
Best Analysts Covering DRTS
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
-4.76%
reiterated a buy rating 10 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -4.76% per trade.
---